Lilly picks Virginia for the first of its four new US manufacturing facilities
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
List view / Grid view
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
Says the Bay Area building’s digital infrastructure will make it one of biopharma’s leading artificial intelligence-powered centres.
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
The University of Cambridge and A*STAR platform aims to enhance fault detection, system monitoring and predictive maintenance.
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
Calls for active pharmaceutical ingredient (API) stockpile to cover around 26 ‘critical drugs’.
The pharma company will add to its existing Chicago site, boosting its active pharmaceutical ingredient production capacity.
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.